Sun Pharma discontinues work on its experimental skin drug SCD-044 after Phase 2 trial results fall short of goals for treating psoriasis and atopic dermatitis
Vepdegestrant is the first and only PROteolysis TArgeting Chimera (PROTAC) evaluated in a Phase 3 clinical trial and the first to show benefit in patients with breast cancer
Bayer expects 2025 to be the most difficult year of its turnaround
Nadda noted that TB treatment coverage in India has increased from 59% to 85%
This Yearbook aims to distinguish those companies that have demonstrated strengths in corporate sustainability
Plans underway to expand screening capacity by 50% for greater accessibility
The Union Budget 2025-26 strengthens India's healthcare sector with an allocation of Rs. 99,858.56 crore, marking a 9.78% rise from Rs. 90,958.63 crore in 2024-25
These initiatives will strengthen the company’s capital base, providing financial flexibility for future
Brings together industry experts to discuss preventive steps to protect pigs from African swine fever and best practises for pig farm management
The segment has immense growth potential driven by the country's increasing healthcare needs, technological innovations, government support, and emerging market opportunities
Subscribe To Our Newsletter & Stay Updated
